Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020


 

State-Of-The-Art in AML Therapy: FLT3, IDH1-2, CD33 & CD123, Venetoclax + Incorporation of Novel Anti-AML Targeted Therapies in 2020

142 views
March 4, 2020
0 Comments
Login to view comments. Click here to Login
Malignant Hematology